680 related articles for article (PubMed ID: 12560443)
1. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
2. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
3. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
4. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kubo K; Miyazaki Y; Murayama T; Shimazaki R; Usui N; Urabe A; Hotta T; Tamura K
Br J Haematol; 2016 Aug; 174(4):563-70. PubMed ID: 27072050
[TBL] [Abstract][Full Text] [Related]
7. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
8. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Rifkin R; Spitzer G; Orloff G; Mandanas R; McGaughey D; Zhan F; Boehm KA; Asmar L; Beveridge R
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):186-91. PubMed ID: 20511163
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
George S; Yunus F; Case D; Yang BB; Hackett J; Shogan JE; Meza LA; Neumann TA; Liang BC
Leuk Lymphoma; 2003 Oct; 44(10):1691-6. PubMed ID: 14692520
[TBL] [Abstract][Full Text] [Related]
11. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Stahel RA; Jost LM; Honegger H; Betts E; Goebel ME; Nagler A
J Clin Oncol; 1997 May; 15(5):1730-5. PubMed ID: 9164179
[TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Zhang W; Jiang Z; Wang L; Li C; Xia J
Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
15. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
17. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
Spunt SL; Irving H; Frost J; Sender L; Guo M; Yang BB; Dreiling L; Santana VM
J Clin Oncol; 2010 Mar; 28(8):1329-36. PubMed ID: 20142595
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Pro B; Fayad L; McLaughlin P; Romaguera J; Hagemeister FB; Rodriguez MA; Goy A; Loyer E; Younes A
Leuk Lymphoma; 2006 Mar; 47(3):481-5. PubMed ID: 16396772
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]